study name and who is ELIGIBLE    ANAVEX2-73-AD – Phase 2b/3 WA only This is a Phase 2b/3 48-week study to evaluate the effects of ANAVEX2-73 on cognition and function after 48 weeks of daily treatment. Anavex2-73 is a novel selective σ1 receptor agonist under investigation to restore homeostasis in patients with serious life-threatening neurodevelopmental and … Continue reading Participate in a Clinical Trial